NO20073655L - Antistoffer mot IL-13 reseptor alfa 1 og anvendelser derav - Google Patents
Antistoffer mot IL-13 reseptor alfa 1 og anvendelser deravInfo
- Publication number
- NO20073655L NO20073655L NO20073655A NO20073655A NO20073655L NO 20073655 L NO20073655 L NO 20073655L NO 20073655 A NO20073655 A NO 20073655A NO 20073655 A NO20073655 A NO 20073655A NO 20073655 L NO20073655 L NO 20073655L
- Authority
- NO
- Norway
- Prior art keywords
- antibodies
- receptor alpha
- antibody
- heavy chain
- variable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05000003 | 2005-01-03 | ||
| EP05002229 | 2005-02-03 | ||
| PCT/EP2006/000005 WO2006072564A1 (fr) | 2005-01-03 | 2006-01-02 | Anticorps contre le recepteur alpha-1 de l'il-13 et leurs utilisations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20073655L true NO20073655L (no) | 2007-08-02 |
Family
ID=36199730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20073655A NO20073655L (no) | 2005-01-03 | 2007-07-17 | Antistoffer mot IL-13 reseptor alfa 1 og anvendelser derav |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US7807158B2 (fr) |
| EP (1) | EP1836226B1 (fr) |
| JP (1) | JP5086098B2 (fr) |
| KR (1) | KR100934894B1 (fr) |
| AR (1) | AR051888A1 (fr) |
| AT (1) | ATE513855T1 (fr) |
| AU (1) | AU2006204480B2 (fr) |
| BR (1) | BRPI0606368A2 (fr) |
| CA (1) | CA2592614C (fr) |
| CR (1) | CR9209A (fr) |
| IL (1) | IL184205A0 (fr) |
| MA (1) | MA29226B1 (fr) |
| MX (1) | MX2007008128A (fr) |
| NO (1) | NO20073655L (fr) |
| NZ (1) | NZ556126A (fr) |
| RU (1) | RU2413736C2 (fr) |
| SG (1) | SG172504A1 (fr) |
| TW (2) | TWI306862B (fr) |
| WO (1) | WO2006072564A1 (fr) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| CA2664343C (fr) | 2006-10-02 | 2016-04-26 | Regeneron Pharmaceuticals, Inc. | Anticorps humains a haute affinite vis-a-vis du recepteur il-4 humain |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| PL2068922T3 (pl) | 2006-10-19 | 2012-11-30 | Csl Ltd | Przeciwciała anty-IL-13R alfa1 i ich zastosowania |
| EP2076285A4 (fr) * | 2006-10-19 | 2010-06-30 | Merck Sharp & Dohme | Antagonistes d'anticorps du récepteur 1 de l'interleukine-13 |
| ES2501947T3 (es) | 2006-10-19 | 2014-10-02 | Csl Limited | Antagonistas de anticuerpos de alta afinidad del receptor alfa 1 de interleucina |
| RU2009148891A (ru) | 2007-06-01 | 2011-07-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Очистка иммуноглобулина |
| JP2010531340A (ja) * | 2007-07-10 | 2010-09-24 | エフ．ホフマン−ラ ロシュ アーゲー | 新規処方物 |
| PT2592148T (pt) * | 2007-10-12 | 2018-11-12 | Hoffmann La Roche | Expressão proteica de múltiplos ácidos nucleicos |
| EP2050764A1 (fr) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Nouveau format d'anticorps bispécifique polyvalent |
| AU2008337904B2 (en) | 2007-12-15 | 2014-02-13 | F. Hoffmann-La Roche Ag | Distinguishing assay |
| ES2549769T3 (es) * | 2009-03-25 | 2015-11-02 | Genentech, Inc. | Anticuerpos anti-FGFR3 y métodos que emplean los mismos |
| US8530392B2 (en) * | 2009-05-13 | 2013-09-10 | Shionogi & Co., Ltd. | Test agent for visceral obesity and use thereof |
| BR112012001843A2 (pt) | 2009-07-30 | 2016-03-15 | Hoffmann La Roche | separador de coluna de cromatografia móvel |
| WO2011038894A1 (fr) | 2009-10-01 | 2011-04-07 | F. Hoffmann-La Roche Ag | Chromatographie sur protéine a |
| KR101653471B1 (ko) | 2009-10-01 | 2016-09-01 | 에프. 호프만-라 로슈 아게 | 다단계 최종 여과 |
| WO2011048043A1 (fr) | 2009-10-19 | 2011-04-28 | F. Hoffmann-La Roche Ag | Anticorps anti igg non à réactivité croisée |
| EP2516460B1 (fr) | 2009-12-22 | 2015-03-04 | F.Hoffmann-La Roche Ag | Agrégation dépendant de la séquence |
| EP2606071B1 (fr) | 2010-08-17 | 2019-12-18 | F.Hoffmann-La Roche Ag | Anticorps anti-igg1 humaine |
| WO2012104278A1 (fr) | 2011-02-02 | 2012-08-09 | F. Hoffmann-La Roche Ag | Support de colonne chromatographique |
| EP2699256B1 (fr) * | 2011-04-21 | 2017-09-27 | The Regents of the University of Colorado, a body corporate | Compositions et méthodes de traitement de maladie de devic |
| KR102502640B1 (ko) | 2012-08-21 | 2023-02-23 | 사노피 바이오테크놀로지 | Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법 |
| CN118286417A (zh) | 2012-09-07 | 2024-07-05 | 瑞泽恩制药公司 | 以il-4r拮抗剂治疗特应性皮炎的方法 |
| TWI755763B (zh) | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
| RS59354B1 (sr) | 2013-06-21 | 2019-10-31 | Sanofi Biotechnology | Postupci lečenja nosne polipoze davanjem il-4r antagonista |
| JP6563910B2 (ja) | 2013-07-04 | 2019-08-21 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 血清サンプル中の抗薬物抗体を検出するための干渉抑制イムノアッセイ |
| TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| AU2014368453B2 (en) | 2013-12-20 | 2020-04-16 | Intervet International B.V. | Caninized murine anti-canine PD-1 antibodies |
| IL315136A (en) | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| PT3110848T (pt) | 2014-09-24 | 2024-03-05 | Regeneron Pharma | Métodos para tratamento de infeção cutânea por administração de um antagonista do il-4r |
| ES2853823T3 (es) | 2014-09-30 | 2021-09-17 | Intervet Int Bv | Anticuerpos de PD-L1 que se unen a PD-L1 canino |
| CA3246946A1 (en) | 2014-11-14 | 2025-11-29 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
| MX388197B (es) | 2015-08-21 | 2025-03-19 | Hoffmann La Roche | Método para la reducción de proteínas de células hospederas en cromatografía de afinidad. |
| HRP20211737T1 (hr) * | 2015-08-21 | 2022-02-18 | F. Hoffmann - La Roche Ag | Postupak za smanjenje proteina stanice domaćina u afinitetnoj kromatografiji |
| US11091556B2 (en) | 2015-12-18 | 2021-08-17 | Intervet Inc. | Caninized human antibodies to human IL-4R alpha |
| ES3014160T3 (en) | 2015-12-18 | 2025-04-21 | Intervet Int Bv | Caninized human antibodies to human and canine il-4r alpha |
| WO2018011405A1 (fr) * | 2016-07-15 | 2018-01-18 | Universität Zürich | Anticorps il-13r alpha1 pour dans le traitement de l'inflammation atopique, de la septicémie et de la neutropénie. |
| KR102872485B1 (ko) | 2016-09-01 | 2025-10-20 | 리제너론 파아마슈티컬스, 인크. | Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법 |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| CA3045944A1 (fr) | 2016-12-07 | 2018-06-14 | Progenity, Inc. | Procedes, dispositifs et systemes de detection du tractus gastro-intestinal |
| WO2018183932A1 (fr) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Traitement d'une maladie du tractus gastro-intestinal à l'aide d'un inhibiteur d'il-13 |
| WO2019028367A1 (fr) | 2017-08-04 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | Méthodes de traitement de l'oesophagite à éosinophiles active |
| PT3515465T (pt) | 2017-08-18 | 2024-03-04 | Regeneron Pharma | Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r |
| US11034768B2 (en) | 2017-10-30 | 2021-06-15 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an IL-4R antagonist |
| WO2019183266A1 (fr) | 2018-03-21 | 2019-09-26 | ALX Oncology Inc. | Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation |
| MX2020012064A (es) | 2018-05-13 | 2021-04-13 | Regeneron Pharma | Metodos para tratar la dermatitis atopica administrando un inhibidor de il-4r. |
| CN113348011B (zh) | 2018-11-19 | 2023-04-18 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| KR20210143246A (ko) | 2019-03-21 | 2021-11-26 | 리제너론 파아마슈티컬스, 인크. | 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용 |
| WO2020197502A1 (fr) | 2019-03-26 | 2020-10-01 | Aslan Pharmaceuticals Pte Ltd | Traitement faisant intervenir un anticorps anti-il-13r ou un fragment de liaison de celui-ci |
| KR20220034878A (ko) | 2019-07-16 | 2022-03-18 | 사노피 바이오테크놀로지 | Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법 |
| US11504426B2 (en) | 2019-08-05 | 2022-11-22 | Regeneron Pharmaceuticals, Inc. | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist |
| JP7736667B2 (ja) | 2019-08-05 | 2025-09-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｉｌ－４ｒアンタゴニストを投与することによるアトピー性皮膚炎の治療方法 |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| WO2022186772A1 (fr) | 2021-03-01 | 2022-09-09 | Aslan Pharmaceuticals Pte Ltd | TRAITEMENT DE LA DERMATITE ATOPIQUE À L'AIDE D'UN ANTICORPS ANTI-IL-13Rα1 OU D'UN FRAGMENT DE LIAISON ASSOCIÉ |
| WO2022186773A1 (fr) | 2021-03-01 | 2022-09-09 | Aslan Pharmaceuticals Pte Ltd | TRAITEMENT DE LA DERMATITE ATOPIQUE À L'AIDE D'UN ANTICORPS ANTI-IL-13Rα1 OU D'UN FRAGMENT DE LIAISON ASSOCIÉ CHEZ UNE POPULATION ALLERGIQUE |
| WO2023048650A1 (fr) | 2021-09-27 | 2023-03-30 | Aslan Pharmaceuticals Pte Ltd | TRAITEMENT DU PRURIT FAISANT INTERVENIR UN ANTICORPS ANTI-IL13Rα1 OU UN FRAGMENT DE LIAISON DE CELUI-CI |
| JP2024534717A (ja) | 2021-09-27 | 2024-09-24 | アスラン ファーマシューティカルズ ピーティーイー リミテッド | 中等症から重症のアトピー性皮膚炎の処置のための方法 |
| WO2023075702A1 (fr) | 2021-10-29 | 2023-05-04 | Aslan Pharmaceuticals Pte Ltd | Formulation d'anticorps anti-il-13r |
| KR20250075749A (ko) | 2022-08-26 | 2025-05-28 | 아슬란 파마슈티컬스 피티이 엘티디 | 항-il13r 항체의 고농도 제형 |
| CN120077070A (zh) | 2022-09-06 | 2025-05-30 | 亚狮康私人有限公司 | 皮炎患者的睡眠缺失或睡眠障碍的治疗 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5614191A (en) | 1995-03-15 | 1997-03-25 | The United States Of America As Represented By The Department Of Health And Human Services | IL-13 receptor specific chimeric proteins and uses thereof |
| ES2334408T3 (es) | 1995-10-23 | 2010-03-09 | Zenyth Operations Pty Ltd | Receptor de hematopoyetina y secuencias geneticas que lo codifican. |
| US5843659A (en) * | 1996-03-21 | 1998-12-01 | Apoptosis Technology, Inc. | Apoptosis gene EI24, compositions, and methods of use |
| EP1449851A4 (fr) | 2001-11-27 | 2005-11-16 | Mochida Pharm Co Ltd | Anticorps de neutralisation du recepteur alpha 1 de l'il13 |
| AR037756A1 (es) * | 2001-12-17 | 2004-12-01 | Bayer Corp | Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma. |
| CA2480059C (fr) | 2002-03-22 | 2015-11-24 | Amrad Operations Pty. Ltd. | Anticorps monoclonal contre le recepteur alpha1 de l'interleukine 13 (il-13ra1) |
| WO2004081186A2 (fr) * | 2003-03-10 | 2004-09-23 | Applera Corporation | Polymorphismes genetiques associes a la stenose, procedes de detection et utilisations associees |
| UA97086C2 (uk) * | 2003-07-15 | 2012-01-10 | Емджен, Інк. | Виділене людське антитіло, яке специфічно зв'язується з фактором росту нервової тканини (ngf) |
-
2005
- 2005-12-30 TW TW094147847A patent/TWI306862B/zh not_active IP Right Cessation
- 2005-12-30 TW TW097137970A patent/TW200902555A/zh unknown
-
2006
- 2006-01-02 WO PCT/EP2006/000005 patent/WO2006072564A1/fr not_active Ceased
- 2006-01-02 KR KR1020077015296A patent/KR100934894B1/ko not_active Expired - Fee Related
- 2006-01-02 NZ NZ556126A patent/NZ556126A/en not_active IP Right Cessation
- 2006-01-02 CA CA2592614A patent/CA2592614C/fr not_active Expired - Fee Related
- 2006-01-02 SG SG2009087206A patent/SG172504A1/en unknown
- 2006-01-02 AT AT06706157T patent/ATE513855T1/de not_active IP Right Cessation
- 2006-01-02 BR BRPI0606368-3A patent/BRPI0606368A2/pt not_active IP Right Cessation
- 2006-01-02 MX MX2007008128A patent/MX2007008128A/es active IP Right Grant
- 2006-01-02 RU RU2007129676/10A patent/RU2413736C2/ru not_active IP Right Cessation
- 2006-01-02 EP EP06706157A patent/EP1836226B1/fr not_active Expired - Lifetime
- 2006-01-02 JP JP2007548835A patent/JP5086098B2/ja not_active Expired - Fee Related
- 2006-01-02 AU AU2006204480A patent/AU2006204480B2/en not_active Expired - Fee Related
- 2006-01-03 US US11/325,197 patent/US7807158B2/en not_active Expired - Fee Related
- 2006-01-03 AR ARP060100010A patent/AR051888A1/es unknown
-
2007
- 2007-06-25 IL IL184205A patent/IL184205A0/en unknown
- 2007-06-26 CR CR9209A patent/CR9209A/es not_active Application Discontinuation
- 2007-07-06 MA MA30048A patent/MA29226B1/fr unknown
- 2007-07-17 NO NO20073655A patent/NO20073655L/no not_active Application Discontinuation
-
2010
- 2010-07-26 US US12/843,225 patent/US20110086026A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20070091180A (ko) | 2007-09-07 |
| MX2007008128A (es) | 2007-07-20 |
| TW200902555A (en) | 2009-01-16 |
| MA29226B1 (fr) | 2008-02-01 |
| RU2007129676A (ru) | 2009-02-10 |
| CA2592614C (fr) | 2015-04-14 |
| AU2006204480A1 (en) | 2006-07-13 |
| EP1836226B1 (fr) | 2011-06-22 |
| ATE513855T1 (de) | 2011-07-15 |
| TWI306862B (en) | 2009-03-01 |
| EP1836226A1 (fr) | 2007-09-26 |
| TW200635945A (en) | 2006-10-16 |
| RU2413736C2 (ru) | 2011-03-10 |
| US20060263356A1 (en) | 2006-11-23 |
| NZ556126A (en) | 2008-09-26 |
| SG172504A1 (en) | 2011-07-28 |
| KR100934894B1 (ko) | 2010-01-07 |
| WO2006072564A1 (fr) | 2006-07-13 |
| JP5086098B2 (ja) | 2012-11-28 |
| BRPI0606368A2 (pt) | 2009-06-23 |
| IL184205A0 (en) | 2007-10-31 |
| AU2006204480B2 (en) | 2011-06-09 |
| AR051888A1 (es) | 2007-02-14 |
| US7807158B2 (en) | 2010-10-05 |
| US20110086026A1 (en) | 2011-04-14 |
| CR9209A (es) | 2007-08-28 |
| HK1112006A1 (en) | 2008-08-22 |
| CA2592614A1 (fr) | 2006-07-13 |
| JP2008526187A (ja) | 2008-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200635945A (en) | Antibodies against IL-13 receptor alpha 1 and uses thereof | |
| NO20074867L (no) | Antistoffer mot CCR5 og anvendelser derav | |
| RU2015147300A (ru) | Гуманизированные антитела к cxcr5, их производные и их применение | |
| CY1117702T1 (el) | Πρωτεϊνες δεσμευομενες με αντιγονο ικανες να δεσμευονται με θυμικη στρωματικη λεμφοποιητινη | |
| LTPA2017038I1 (lt) | Didelio giminingumo antikūnai prieš žmogaus IL-6 receptorių | |
| NZ607711A (en) | Antibodies directed to her-3 and uses thereof | |
| WO2007117577A3 (fr) | Anticorps humains à haute affinité dirigés contre le récepteur de l'il-18 humaine | |
| PE20110801A1 (es) | Anticuerpos con reactividad cruzada y biespecificos anti-il-17a/f | |
| RU2013138469A (ru) | АНТИТЕЛА К ИНТЕРЛЕЙКИНУ-1α И СПОСОБЫ ПРИМЕНЕНИЯ | |
| NO20090224L (no) | Anti-IL-6 monoklonale antistoffer og anvendelser derav | |
| CO6231009A2 (es) | Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes | |
| ATE395364T1 (de) | Gegen procalcitonin gerichtete antikörper, ihre herstellung und verwendung | |
| BRPI0821168B8 (pt) | anticorpo isolado que se liga ao il-21 humano, ou um fragmento deste, usos de dito anticorpo ou fragmento, e, hibridoma | |
| JP2012507294A5 (fr) | ||
| PE20120429A1 (es) | Proteinas de enlace de miostatina | |
| NZ700473A (en) | Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof | |
| NO20084650L (no) | Modifiserte humaniserte anti-interleukin-18 antistoffer | |
| ES2572177T3 (es) | Anticuerpos neutralizantes anti-B7RP1 humanos | |
| NZ602780A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| PE20080036A1 (es) | Anticuerpos humanos para la interleucina-13 (il13) | |
| RU2011144166A (ru) | Способы применения антител к il-22 человека | |
| ATE512986T1 (de) | Antikörper gegen clostridium difficile-toxine und ihre verwendung | |
| NO20063026L (no) | Antistoffer | |
| EA032189B9 (ru) | Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |